These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 3880771)

  • 1. Serum prostacyclin binding defects in thrombotic thrombocytopenic purpura.
    Wu KK; Hall ER; Rossi EC; Papp AC
    J Clin Invest; 1985 Jan; 75(1):168-74. PubMed ID: 3880771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies of the pathogenesis and management of thrombotic thrombocytopenic purpura.
    Kakishita E; Nakajima T; Suehiro A; Koyama T; Ueda M; Tsujioka H; Yoshimoto H
    Pol J Pharmacol; 1996; 48(2):179-84. PubMed ID: 9112648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of vascular thrombosis by products of arachidonic acid metabolism.
    Wu KK; Hall ER; Papp A
    Clin Physiol Biochem; 1984; 2(2-3):84-90. PubMed ID: 6435930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prostacyclin stability in thrombotic thrombocytopenic purpura. Japan Working Group on TTP].
    Koyama T; Kakishita E
    Nihon Rinsho; 1993 Jan; 51(1):142-5. PubMed ID: 8433507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accelerated prostacyclin degradation in the thrombotic thrombocytopenic purpura.
    Chen YC; McLeod B; Hall ER; Wu KK
    Lancet; 1981 Aug; 2(8241):267-9. PubMed ID: 6114320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous prostacyclin (as epoprostenol) infusion in thrombotic thrombocytopenic purpura. Four case reports and review of the literature. Italian Cooperative Group for Thrombotic Thrombocytopenic Purpura.
    Bobbio-Pallavicini E; Porta C; Tacconi F; Gugliotta L; Centurioni R; Vianelli N; Billio A; Ascari E
    Haematologica; 1994; 79(5):429-37. PubMed ID: 7843629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitation of serum prostacyclin-binding in thrombotic thrombocytopenic purpura.
    Tsai AL; Manner CE; Rudersdorf T; Wu KK
    Thromb Res; 1988 Sep; 51(6):583-92. PubMed ID: 3055418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding of prostacyclin by plasma glycoproteins.
    Papp AC; Hall ER; Wu KK
    Prostaglandins; 1985 Dec; 30(6):1057-68. PubMed ID: 3911293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of PGI2 activity by serum proteins: serum albumin but not high density lipoprotein is the PGI2 binding and stabilizing protein in human blood.
    Tsai AL; Hsu MJ; Patsch W; Wu KK
    Biochim Biophys Acta; 1991 Dec; 1115(2):131-40. PubMed ID: 1764464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Separate receptors for prostacyclin and prostaglandin E2 on human gel-filtered platelets.
    Eggerman TL; Andersen NH; Robertson RP
    J Pharmacol Exp Ther; 1986 Mar; 236(3):568-73. PubMed ID: 2869139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction between lymphocytes and platelets in the synthesis of prostacyclin.
    Wu KK; Papp AC; Manner CE; Hall ER
    J Clin Invest; 1987 Jun; 79(6):1601-6. PubMed ID: 3108319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet hyperactivity in acute myocardial infarction in man--effects of prostacyclin.
    Mueller HS; Rao PS; Greenberg MA; Buttrick PM; Sussman II; Levite HA; Grose RM; Perez-Davila V; Strain JE; Spaet TH
    Herz; 1986 Apr; 11(2):116-26. PubMed ID: 2939012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stability of prostacyclin in human and rabbit whole blood and plasma.
    Lucas FV; Skrinska VA; Chisolm GM; Hesse BL
    Thromb Res; 1986 Aug; 43(4):379-87. PubMed ID: 3532417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum prostacyclin binding and half-life in normal and hypertensive pregnant women.
    O'Brien WF; Knuppel RA; Saba HI; Angel JL; Benoit R; Bruce A
    Obstet Gynecol; 1989 Jan; 73(1):43-6. PubMed ID: 2642327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Very low levels of 6-keto-prostaglandin F1 alpha in human plasma.
    Siess W; Dray F
    J Lab Clin Med; 1982 Mar; 99(3):388-98. PubMed ID: 7035588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombotic thrombocytopenic purpura and the haemolytic-uraemic syndrome: evolving concepts of pathogenesis and therapy.
    Byrnes JJ; Moake JL
    Clin Haematol; 1986 May; 15(2):413-42. PubMed ID: 3524932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological half-life of prostacyclin and 6-oxo-PGF1 alpha levels in plasma of patients with colonic cancer.
    Polterauer P; Sinzinger H; Peskar BA
    Prostaglandins Leukot Med; 1986 Jun; 22(3):249-58. PubMed ID: 3523543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased plasma-6-oxo-PGF1-alpha but normal PGI2 half-life in patients with maxillo-facial tumors.
    Porteder H; Matejka M; Kment G; Nell A; Sinzinger H
    Prog Clin Biol Res; 1987; 242():123-9. PubMed ID: 3313409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet aggregating activity of plasma in patients with thrombotic thrombocytopenic purpura evaluated by a particle counting method using light scattering.
    Suehiro A; Yoshimoto H; Higasa S; Kakishita E
    Int J Hematol; 1999 Jul; 70(1):40-6. PubMed ID: 10446494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic disposition of prostacyclin in humans.
    Brash AR; Jackson EK; Saggese CA; Lawson JA; Oates JA; FitzGerald GA
    J Pharmacol Exp Ther; 1983 Jul; 226(1):78-87. PubMed ID: 6345756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.